Anne Fleur Kortekaas-Rijlaarsdam

CHAPTER 2 50 Supplementary material Table E2.3 Risk of bias index cross-over trials (Cochrane 16.4.3) Authors (year) I. Cross-over design suitable? II. Biased from carry-over effects? III. First period data available (if relevant, see II) IV. Correct (paired) analysis? V. Comparable with results from parallel trials? VI. Order of treatments randomized? VII. Drop-out reported? Overall score* (Childress et al., 2017) Between-subject design Not applicable Not applicable Yes, between-subject Not applicable Yes, assignment to treatment groups randomized Yes Not applicable (Kortekaas-Rijlaarsdam et al., 2017b) Yes No, sequence as fixed factor in model Irrelevant Yes Yes Yes Yes 5 (Wigal et al., 2017) Between-subject design Not applicable Not applicable Yes, between-subject Not applicable Yes, assignment to treatment groups randomized Yes Not applicable (Froehlich et al., 2014)** Between-subject design Not applicable Not applicable Yes, between-subject Not applicable Yes, assignment to treatment groups randomized Yes Not applicable (Robb et al., 2014) Yes Not reported Not reported Yes Not reported Yes Yes 4 (Wigal et al., 2014) Yes No, sequence as fixed factor in model Irrelevant Yes Yes Yes Yes 5 (Grizenko et al., 2013) Yes Not reported Not reported Yes Not reported Yes Yes 4 (Murray et al., 2011) Yes No Irrelevant Yes Yes Yes Yes 5 (Wigal et al., 2011) Yes No Irrelevant Yes Yes Yes Yes 5 (Schulz et al., 2010) Yes Not reported Not reported Yes Not reported Yes Yes 4 (Bental & Tirosh, 2008) Yes Yes Yes Yes No Yes Yes 5 (Muniz et al., 2008) Yes No, sequence as fixed factor in model Irrelevant Yes Yes Yes Yes 5 (Rubinsten et al., 2008) Yes Not reported Not reported Yes Not reported Yes No 3 (Wilens et al., 2008) Yes No, sequence as fixed factor in model Irrelevant Yes Yes Yes Yes 5 (Gorman et al., 2006) Yes No, drug order as between-subject factor Irrelevant Yes Yes Yes Yes 5 (McGough et al., 2006) Yes No, sequence as fixed factor Irrelevant Yes Yes Yes Yes 5